Publikationen Hass2

Titel:Originalarbeiten Dr. med. H.G. Hass
Einrichtung:Paracelsus-Klinik Scheidegg

Hass HG, Bock T, Nehls O, Kaiser S. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol. 2009 May 21. [Epub ahead of print]

Hass HG, Klein R, Nehls O, Kaiser S. Thyroid Disorders and Occurrence of Nonorgan-specific Autoantibodies (NOSA) in Patients With Chronic Hepatitis C Before and During Antiviral Induction Therapy With Consensus Interferon (Interferon Alfacon-1). J Clin Gastroenterol. 2009 Feb 25. [Epub ahead of print]

Hass HG, Denzlinger C. Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report. Z Gastroenterol. 2009; 47: 27-9.

Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol. 2008; 14: 2501-10.

Nehls O, Hass HG, Okech T, Zenner S, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Porschen R, Gregor M, Klump B. Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. Int J Colorectal Dis. 2009; 24: 655-63.

Hass HG, Schmidt A, Nehls O, Kaiser S. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions. Oral Oncol. 2008; 44: 78-85.

Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008; 98: 309-15.

Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007; 96: 1409-18.

Hass HG, Kaiser S. A 56-year-old female patient with Raynaud's syndrome, increased liver enzymes and neuropsychiatric symptoms. Dtsch Med Wochenschr. 2006; 131: 2213-6.

Nehls O, Hass HG, Weber P, Dette S, Lauer UM, Schlemmer HP, Oehlert M, Gregor M, Klump B. Sarcoidosis mimicking cholangiocarcinoma. Endoscopy. 2006; 38 Suppl 2: E65-6.

Hass HG, Kreysel C, Fischinger J, Menzel J, Kaiser S. High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. World J Gastroenterol. 2005; 11: 5342-6.

Hass HG, Nägele T, Seeger U, Hösl F, Gregor M, Kaiser S. Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS). Z Gastroenterol. 2005; 43: 373-8.

Naegele T, Seeger U, Hass H, Kueker W, Heckl S, Klose U. Localized proton spectroscopy in hepatic encephalopathy: advantage of 3T high field for discrimination of glutamine and glutamate. Magnetom Flash 2004; 28: 50-53.

Hass HG, Nehls O, Gregor M, Kaiser S, Kreysel C. Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses. Dig Liver Dis. 2004; 36: 367-8.

Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer. 2002; 87: 702-4.